Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
Patients with cystic fibrosis (CF) develop pulmonary disease secondary to airway infection and dysregulated inflammation. Therapeutic innovations such as nebulized antimicrobial therapy targeting specific pathogens have resulted in improvements in quality of life and life expectancy. Aztreonam lysin...
Main Authors: | Elizabeth Claire Elson, Joel Mermis, Deepika Polineni, Christopher M Oermann |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-04-01
|
Series: | Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine |
Online Access: | https://doi.org/10.1177/1179548419842822 |
Similar Items
-
Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis
by: Martha K Daddario, et al.
Published: (2010-10-01) -
Evidence for the efficacy of aztreonam for inhalation solution in the management of in patients with cystic fibrosis
by: Christine Hansen, et al.
Published: (2015-02-01) -
Lung clearance index to detect the efficacy of Aztreonam lysine inhalation in patients with cystic fibrosis and near normal spirometry - A single-centre feasibility study.
by: Helmut Ellemunter, et al.
Published: (2019-01-01) -
Pharmacotherapy of cystic fibrosis: inhaled antibiotics
by: N. I. Kapranov
Published: (2013-12-01) -
Bronchial reactivity to inhaled hypertonic saline solutions in children with cystic fibrosis
by: S.I. Ilchenko, et al.
Published: (2022-09-01)